reviewed april 2026|next review october 2026|88 physicians psi has verified|20 published studies
P21 (NSI-189 Peptide Fragment)
P21 is an 11-amino-acid synthetic peptide fragment derived from CNTF (ciliary neurotrophic factor), designed to cross the blood-brain barrier and stimulate hippocampal neurogenesis without the systemic side effects of the parent growth factor, with all published data from a single research group.
Evidence landscape: 20 published studies
20 published items. 0 human studies and 20 animal studies.
- 20 Animal
Not FDA-approved. Not approved by any regulatory authority. Research compound only. No clinical development program has been initiated.
Available as a research compound from peptide suppliers. No pharmaceutical-grade formulation exists. All use is experimental and outside any approved indication.
CNTF-derived synthetic peptide designed for neurogenesis. All 20 published studies originate from a single research group at the City University of New York (CUNY). No independent replication exists. No human studies of any kind.
PSI Assessment
A synthetic peptide fragment derived from CNTF (ciliary neurotrophic factor), P21 was designed to cross the blood-brain barrier and stimulate neurogenesis without the systemic side effects of the parent growth factor. Animal studies show P21 increases hippocampal neurogenesis and improves spatial memory in models of Alzheimer's disease. The compound gained attention in the nootropic community after a series of rodent studies from a single research group at the City University of New York showed cognitive improvements in transgenic Alzheimer's mice. No human studies have been conducted.
Stimulates hippocampal neurogenesis in animal models. All data from a single research group. No human studies of any kind.
The mechanism is CNTF-pathway activation without full CNTF receptor engagement. Full-length CNTF produces dramatic systemic effects including anorexia and cachexia (muscle wasting) that prevented its clinical development. P21 was truncated to retain the neurogenic signaling while avoiding the systemic CNTF receptor activation that causes these side effects. The peptide is designed to cross the blood-brain barrier. In animal models, it increases new neuron production in the hippocampal dentate gyrus, a brain region critical for memory formation.
What the evidence supports
P21 increases hippocampal neurogenesis in rodent models, including transgenic Alzheimer's mice. Spatial memory improvements are documented in multiple animal studies. The CNTF-derived design successfully avoids the systemic side effects of the parent growth factor while retaining neurogenic activity. Blood-brain barrier penetration is demonstrated in animals.
What is not yet established
Human safety, pharmacokinetics, or efficacy data of any kind. Independent replication outside the originating research group (CUNY). Whether the neurogenic effects observed in rodents translate to humans. Long-term effects of stimulating neurogenesis.
Research Evidence
The findings below reflect the single-lab evidence base and highlight the critical absence of independent replication.
Evidence by condition
Evidence dimensions across P21 research areas. Neurogenesis has consistent animal data from the originating laboratory. Alzheimer's research has transgenic mouse model data. Cognitive enhancement is extrapolated from animal memory improvements. Controlled human data has not been published for any indication.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Neurogenesis | ||||
| Alzheimer's Research | ||||
| Cognitive Enhancement |
P21 increases hippocampal neurogenesis in rodent models of Alzheimer's disease, including transgenic mice expressing human tau and amyloid pathology. Spatial memory improvements are documented across multiple studies.
All studies originate from the same research group at CUNY. While the results are internally consistent, the absence of independent replication is the most significant limitation.
The CNTF-derived design successfully avoids the systemic side effects of full-length CNTF (anorexia, cachexia) while retaining the neurogenic signaling component. Blood-brain barrier penetration is demonstrated in animals.
Full-length CNTF's clinical development was abandoned due to severe systemic side effects. P21 was designed specifically to retain the beneficial neurogenic effects while eliminating the systemic activation that caused those problems.
All 20 published studies on P21 originate from a single research group at CUNY. No independent laboratory has published research on P21. No human studies of any kind have been conducted.
Single-source evidence without independent replication carries substantially lower confidence regardless of internal consistency. The nootropic community interest in P21 is based entirely on animal data from one laboratory.
0 Human|20 Animal|0 Reviews
View all 20 indexed studiesHow P21 (NSI-189 Peptide Fragment) Works
P21 is a synthetic peptide fragment, meaning it is a small piece of a larger protein that has been recreated in the laboratory. It is derived from CNTF (ciliary neurotrophic factor), a growth factor that promotes neuron survival and growth. The full CNTF protein caused severe side effects in clinical trials, so P21 was designed to keep only the brain-growth-promoting part while removing the parts that caused systemic problems.
Mimics a brain growth factor to help grow new neurons and strengthen brain connections.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
P21 is an 11-amino-acid synthetic peptide derived from the active region of CNTF with an adamantane modification for blood-brain barrier penetration. It inhibits leukemia inhibitory factor (LIF) signaling, which normally suppresses neurogenesis, thereby disinhibiting neural stem cell proliferation and differentiation in the dentate gyrus. It also increases BDNF levels. The design avoids full CNTF receptor (CNTFR/LIFR/gp130 complex) activation, preventing the anorexia and cachexia that halted CNTF clinical development.
What is P21 (NSI-189 Peptide Fragment) being studied for?
Researchers are studying P21 (NSI-189 Peptide Fragment) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for P21 (NSI-189 Peptide Fragment) overall. This means a compound can have human studies for one condition but only animal data for another.
Neurogenesis
·Animal StudiesP21 increases new neuron production in the hippocampal dentate gyrus in rodent models. The effect is consistent across multiple studies from the originating laboratory.
Limitations: All data from a single research group (CUNY). No independent replication. No human neurogenesis data.
Alzheimer's Research
·Animal StudiesTransgenic Alzheimer's mouse models show cognitive improvements and reduced tau hyperphosphorylation with P21 treatment.
Limitations: Rodent Alzheimer's models have a poor track record of predicting human drug success. All data from one lab. No human studies.
Cognitive Enhancement
·PreclinicalSpatial memory improvements in animal models. No data in healthy animals or humans for cognitive enhancement beyond disease models.
Limitations: Cognitive improvement data comes from disease models (Alzheimer's mice), not healthy cognition. No human data of any kind.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not approved by any regulatory authority. No clinical development program has been initiated. Research compound only.
Availability: Available from research peptide suppliers. No pharmaceutical-grade formulation. All use is experimental.
Class context: No human safety data of any kind. Designed to avoid the systemic CNTF side effects (anorexia, cachexia) that prevented the parent growth factor from clinical development. Animal studies report no significant adverse effects, but the evidence base is limited to a single research group.
P21 has no human safety data. The compound was designed specifically to avoid the severe systemic side effects of full-length CNTF (anorexia and muscle wasting). Animal studies from the originating laboratory report no significant adverse effects. The long-term consequences of stimulating hippocampal neurogenesis are not established.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a P21 (NSI-189 Peptide Fragment) discussion.
Comparison and Related Research
P21 is most often compared with other neuroprotective and nootropic compounds, particularly those with clinical data that P21 lacks.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Demonstrated that P21, a peptide derived from ciliary neurotrophic factor (CNTF), rescued age-related cognitive decline in an animal model. Treatment enhanced neurogenesis in the hippocampus and improved performance on memory tasks, supporting the hypothesis that neurotrophic peptides can counteract cognitive aging.Bolognin S et al., 2014 in Neurobiol Aging. View on PubMed
- 2.Showed that a CNTF-derived tetrapeptide (the basis for P21) promoted new neuron formation in the adult hippocampus and enhanced synaptic plasticity. Treated animals showed improved spatial memory, providing the first direct evidence that this small peptide could stimulate the brain's capacity to generate new neurons and strengthen neural connections.Blanchard J et al., 2010 in J Alzheimers Dis. View on PubMed
- 3.Extended the evidence for CNTF-derived peptide effects on brain plasticity by demonstrating enhanced neurogenesis specifically in the dentate gyrus, a hippocampal subregion critical for memory encoding. The study also documented improvements in dendritic complexity and synaptic marker expression.Chohan MO et al., 2011 in Neurobiol Aging. View on PubMed
- 4.Evaluated chronic oral administration of the neurotrophic peptide P21 in a triple-transgenic Alzheimer's disease mouse model. Treatment reduced tau pathology and amyloid burden while improving cognitive performance, suggesting potential disease-modifying rather than merely symptomatic effects in neurodegeneration.Kazim SF & Bhatt K, 2014 in Neurobiol Dis. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.